Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis

British Medical Journal,  April 8, 2000  by Darren M Ashcroft,  Alain Li Wan Po,  Hywel C Williams,  Christopher E M Griffiths

• E-mail
• Print
• Link

Potent topical steroids are as effective as calcipotriol but this has to be balanced against possible long term systemic effects. The trials have generally been short term, and the advantage of calcipotriol in longer term trials over the cheaper alternatives, particularly regarding improved quality of life and lower relapse rates has yet to be shown

[1] Rea JN, Newhouse ML, Halil T Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med 1976;30:107-14.

[2] Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533-7.

[3] Gawkrodger DJ on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists. Current management of psoriasis. J Dermatol Treat 1997;8:27-55.

[4] Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica 1978;157:238-44.

[5] Rothman KJ. Modern epidemiology. Boston: Little, Brown;1986:177-233.

[6] Li Wan Po A, Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. BMJ 1997;315:1565-71.

[7] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.

[8] Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomised clinical trials. Stat Med 1991; 10:1665- 77.

[9] Wehr R, Gibson J, Epinette W, Pincus S, Chesnut C, Goffe B, et al. The safety of topically applied calcipotriene ointment 0.005% (a vitamin [D.sub.3] analogue) as measured by blood, urine and bone density analysis in psoriatic patients [abstract]. Skin Pharmacol 1992;5:206-7.

[10] Griffiths WAD. Comparison of calcipotriol ointment and betamethasone ointment in the treatment of psoriasis vulgaris (parallel group). Presented at Dalvonex, calcipotriol. A totally new treatment in psoriasis [abstract]. Athens, Greece, 1991.

[11] RT Plott. A double-blind study comparing the efficacy of diflorasone diacetate ointment 0.05% vs calcipotriene ointment 0.05% in the treatment of psoriasis [abstract]. Presented at the 54th annual meeting of the American Academy of Dermatology. Washington, DC;996:P-317.

[12] Bourke JF, Featherstone S, Iqbal SJ, Hutchinson PE. A double-blind comparison of topical calcitriol (3 [micro]g/g) and calcipotriol (50 [micro]g/g) in the treatment of chronic plaque psoriasis vulgaris [abstract]. Br J Dermatol 1995;133(suppl 45):17.

[13] Scarpa C. Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid. Acta Derm Venereol (Stockh) 1994;186(suppl):47.

[14] Hutchinson PE, Berth-Jones J, Chalmers RJG, Chu AC, Griffiths WAD, Klaber MR. A comparison of calcipotriol ointment and short contact dithranol in the treatment of chronic plaque psoriasis [abstract]. Br J Dermatol 1992;127(suppl 40):17.

[15] Jurgensen HJ. A comparative study of Dovonex ointment and Dithrocream in treating psoriasis vulgaris [abstract]. Presented at the Dovonex Satellite symposium, 2nd Congress of the European Academy of Dermatology and Venereology. Athens, Greece 1991.